WallStSmart

InterCure Ltd. (INCR)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 5890% more annual revenue ($14.56B vs $243.12M). VTRS leads profitability with a -2.0% profit margin vs -13.2%. VTRS earns a higher WallStSmart Score of 50/100 (C-).

INCR

Hold

38

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: 0.62

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: 0.55

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INCR2 strengths · Avg: 9.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
23.9%8/10

Revenue surging 23.9% year-over-year

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Areas to Watch

INCR4 concerns · Avg: 2.5/10
Market CapQuality
$55.23M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Return on EquityProfitability
-9.0%2/10

ROE of -9.0% — below average capital efficiency

EPS GrowthGrowth
-84.7%2/10

Earnings declined 84.7%

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-2.0%2/10

ROE of -2.0% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.552/10

Distress zone — elevated risk

Profit MarginProfitability
-2.0%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : INCR

The strongest argument for INCR centers on Price/Book, Revenue Growth. Revenue growth of 23.9% demonstrates continued momentum.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : INCR

The primary concerns for INCR are Market Cap, Operating Margin, Return on Equity.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

INCR profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.

VTRS carries more volatility with a beta of 0.90 — expect wider price swings.

INCR is growing revenue faster at 23.9% — sustainability is the question.

VTRS generates stronger free cash flow (348M), providing more financial flexibility.

Bottom Line

VTRS scores higher overall (50/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

InterCure Ltd.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Syneos Health, Inc., a contract research organization, provides various clinical development services for the medical device and biopharmaceutical industries in North America, Europe, the Middle East and Africa, Asia-Pacific, and Latin America. The company is headquartered in Raleigh, North Carolina.

Visit Website →

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?